CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer

Acta Oncologica

Volumn 46, Issue 3, 2007, Pages 361-366

  Pan, Ji Hong ^a,b   Han, Jin Xiang ^a,b   Wu, Jian Mei ^a   Sheng, Li Jun ^c   Huang, Hai Nan ^a  

^a BEIJING HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 34247218082     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600902197     Document Type: Article

References (17)

1. Ashizawa T, Miyoshi K, Asada M, Kobayashi E, Okabe M, Morimoto M, et al. Anti-tumor activity of Navelbine (vinorelbine ditartrate), a new vinca alkaloid analog. Jpn J Cancer Chemother 1993;20:59-66.
2. Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meininger V. In situ analysis of the action of Navelbine on various types of microtubules using immuno-fluorescence. Semin Oncol 1989;16(Suppl 4):5-8.
3. Goa KL, Faulds D. Vinorelbine: A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 1994;5:200-34.
4. Zhou XJ, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs 1992;44(Suppl 4):1-16.
5. Toso C, Lindley C. Vinorelbine: A novel vinca alkaloid. Am J Health-Syst Pharm 1995;52:1287-304.
6. Pallis AG, Agelidou A, Papakotoulas P, Tsaroucha A, Agelidou M, Agelaki S, et al. A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer 2006;52:165-71. Epub 2006 Mar 24.
7. Krikorian A, Rahmani R, Bromet M, Bore P, Cano JP. Pharmacokinetics and metabolism of Navelbine. Semin Oncol 1989;16(Suppl 4):21-5.
8. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, et al. Gene structure of CYP3A4, an adult-specific orm of cytochrome P450 in human livers and its transcriptional control. Eur J Biochem 1993;218:585-95.
9. Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R. Human liver microsomal cytochrome P450 3A enzymes mediated vindesine biotransformation: Metabolic drug interactions. Biochem Pharmacol 1993;45:853-61.
10. Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions. Cancer Res 1993;53:5121-6.
11. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
12. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1′- hydoxoymidazolam in Chinese with different CY3A5 genotypes. Drug Metab Dispos 2002;30:1491-6.
13. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993;53:410-8.
14. Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, Segawa T, Hiramatsu Y. The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol 2005;19:1170-80.
15. Zhang J, Huang W, Qatanani M, Evans RM, Moore DD. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J Biol Chem 2004;279:49517-22.
16. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21:3016-24.
17. Scagliotti GV, DeMarinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91.